HL7 FHIR Implementation Guide: Common Terminology Criteria (CTC) Adverse Events Release 1 - DRAFT
0.0.1 - DRAFT United States of America flag

HL7 FHIR Implementation Guide: Common Terminology Criteria (CTC) Adverse Events Release 1 - DRAFT, published by HL7 International Clinical Interoperability Council. This guide is not an authorized publication; it is the continuous build for version 0.0.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/standardhealth/fsh-ae/ and changes regularly. See the Directory of published versions

: medadmin-doxorubicin-persona-2 - JSON Representation

Raw json | Download


{
  "resourceType" : "MedicationAdministration",
  "id" : "medadmin-doxorubicin-persona-2",
  "meta" : {
    "profile" : [
      🔗 "http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-medication-administration"
    ]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: MedicationAdministration</b><a name=\"medadmin-doxorubicin-persona-2\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource MedicationAdministration &quot;medadmin-doxorubicin-persona-2&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"http://hl7.org/fhir/us/mcode/2021May/StructureDefinition-mcode-cancer-related-medication-administration.html\">Cancer-Related Medication Administration</a></p></div><p><b>status</b>: completed</p><p><b>category</b>: Outpatient <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-medicationrequest-category.html\">MedicationRequest Category Codes</a>#outpatient)</span></p><p><b>medication</b>: doxorubicin hydrochloride 20 MG per 10 ML Injection <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-rxNorm.html\">RxNorm</a>#1790099)</span></p><p><b>subject</b>: <a href=\"Patient-PatientPersona2.html\">Patient/PatientPersona2</a> &quot; C.&quot;</p><p><b>effective</b>: 2020-12-01</p><p><b>reasonReference</b>: <a href=\"Condition-primary-cancer-condition-persona-2.html\">Condition/primary-cancer-condition-persona-2</a></p><p><b>request</b>: <a href=\"MedicationRequest-medrequest-doxorubicin-persona-2.html\">MedicationRequest/medrequest-doxorubicin-persona-2</a></p><p><b>note</b>: doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects. (By Practitioner/us-core-practitioner-nancy-oncology-nurse @2020-12-01)</p><h3>Dosages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Route</b></td><td><b>Dose</b></td></tr><tr><td style=\"display: none\">*</td><td>Intravenous route (qualifier value) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#47625008)</span></td><td>105.96 mg<span style=\"background: LightGoldenRodYellow\"> (Details: UCUM code mg = 'mg')</span></td></tr></table></div>"
  },
  "status" : "completed",
  "category" : {
    "coding" : [
      {
        "system" : "http://terminology.hl7.org/CodeSystem/medicationrequest-category",
        "code" : "outpatient"
      }
    ]
  },
  "medicationCodeableConcept" : {
    "coding" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "code" : "1790099",
        "display" : "doxorubicin hydrochloride 20 MG per 10 ML Injection"
      }
    ]
  },
  "subject" : {
    🔗 "reference" : "Patient/PatientPersona2"
  },
  "effectiveDateTime" : "2020-12-01",
  "reasonReference" : [
    {
      🔗 "reference" : "Condition/primary-cancer-condition-persona-2"
    }
  ],
  "request" : {
    🔗 "reference" : "MedicationRequest/medrequest-doxorubicin-persona-2"
  },
  "note" : [
    {
      "authorReference" : {
        🔗 "reference" : "Practitioner/us-core-practitioner-nancy-oncology-nurse"
      },
      "time" : "2020-12-01",
      "text" : "doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects."
    }
  ],
  "dosage" : {
    "route" : {
      "coding" : [
        {
          "system" : "http://snomed.info/sct",
          "code" : "47625008",
          "display" : "Intravenous route (qualifier value)"
        }
      ]
    },
    "dose" : {
      "value" : 105.96,
      "unit" : "mg",
      "system" : "http://unitsofmeasure.org",
      "code" : "mg"
    }
  }
}